Dr. Breelyn Wilky discusses challenges that patients with GIST face and shares advice with those who feel overwhelmed by the ...

Breelyn Wilky, MD, explains when patients with gastrointestinal stromal tumor should be referred for clinical trials.

Breelyn Wilky, MD, discusses what key molecular insights in GIST management community oncologists should prioritize today.

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can help guides treatment decisions.

Upper GI cancer treatment depends on a number of factors, and may include treatments such as surgery, chemotherapy, radiation ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end ...

While cancers such as breast, lung, and prostate frequently dominate public health discussions, there is a far less recognised but equally aggressive form - sarcoma.It affects thousands across the UK ...

When most people think of cancer, names like breast, lung, or prostate cancer instantly come to mind. However, there’s another, lesser-known form called sarcoma that affects thousands of people in the ...

Gastrointestinal stromal tumors are among the first solid tumors for which cancer-(cell-)specific therapy became available. What is its pathogenesis, therapy strategies and drug resistance mechanisms?

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours ...